Dx & Vx Co., Ltd. (KOSDAQ:180400)
4,895.00
-125.00 (-2.49%)
At close: Apr 9, 2026
Dx & Vx Revenue
In the year 2025, Dx & Vx had annual revenue of 29.36B KRW, down -13.52%. Dx & Vx had revenue of 7.55B in the quarter ending December 31, 2025, a decrease of -1.46%.
Revenue
29.36B
Revenue Growth
-13.52%
P/S Ratio
16.53
Revenue / Employee
n/a
Employees
n/a
Market Cap
485.25B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 29.36B | -4.59B | -13.52% |
| Dec 31, 2024 | 33.95B | -7.30B | -17.69% |
| Dec 31, 2023 | 41.24B | 9.06B | 28.15% |
| Dec 31, 2022 | 32.18B | 24.71B | 330.83% |
| Dec 31, 2021 | 7.47B | -226.13M | -2.94% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Green Cross Medical Science | 108.41B |
| Seoulin Bioscience | 77.09B |
| Cytogen | 26.05B |
| Protia | 15.12B |
| HLB Panagene | 15.05B |
| 3billion | 11.71B |
| GENINUS | 10.48B |
| Median Diagnostics | 7.86B |